Cargando…
First-in-human phase 1 trial of the safety and immunogenicity of a recombinant adenovirus serotype 5 HVR48 (rAd5HVR48) HIV-1 vaccine
Autores principales: | Walsh, SR, Seaman, MS, Johnson, JA, Tucker, RP, Krause, KH, Weijtens, M, Pau, MG, Goudsmit, J, Dolin, R, Barouch, DH, Baden, LR |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441301/ http://dx.doi.org/10.1186/1742-4690-9-S2-O52 |
Ejemplares similares
-
HvrBase++: a phylogenetic database for primate species
por: Kohl, Jochen, et al.
Publicado: (2006) -
OA05-06 LB. First-in-human Phase 1 safety and immunigenicity of an adenovirus serotype 26 HIV-1 vaccine vector
por: Baden, LR, et al.
Publicado: (2009) -
Role of HVR1 sequence similarity in the cross-genotypic neutralization of HCV
por: Mosa, Alexander I., et al.
Publicado: (2020) -
Monoclonal Antibodies Directed toward the Hepatitis C Virus Glycoprotein E2 Detect Antigenic Differences Modulated by the N-Terminal Hypervariable Region 1 (HVR1), HVR2, and Intergenotypic Variable Region
por: Alhammad, Yousef, et al.
Publicado: (2015) -
HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice
por: Prentoe, Jannick, et al.
Publicado: (2016)